Systematic review of pharmacoeconomic studies of pharmacogenomic tests

Cost-Effectiveness of Using Pharmacogenetic Information in Warfarin Dosing for Patients With Nonvalvular Atrial Fibrillation

(2013) Mark H. Eckman   ANNALS OF INTERNAL MEDICINE

Innovative Diagnostic Technologies and Their Significance for Personalized Medicine

(2012) Kewal K. Jain   Molecular Diagnosis & Therapy

Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer

(2010) Valesca P. Retèl et al.   EUROPEAN JOURNAL OF CANCER

Thiopurine S-Methyltranferase Testing in Idiopathic Pulmonary Fibrosis: A Pharmacogenetic Cost-Effectiveness Analysis

(2010) Jared T. Hagaman et al.   LUNG

US pharmacies broaden access to pharmacogenetic tests

(2010) Malorye Allison   NATURE BIOTECHNOLOGY

Personalized genomic information: preparing for the future of genetic medicine

(2010) Alan E. Guttmacher et al.   NATURE REVIEWS GENETICS

Cost-Effectiveness Analysis of Recurrence Score-Guided Treatment Using a 21-Gene Assay in Early Breast Cancer

(2010) D. T. Tsoi et al.   ONCOLOGIST

Economic Efficiency of Genetic Screening to Inform the Use of Abacavir Sulfate in the Treatment of HIV

(2010) Teresa L. Kauf et al.   PHARMACOECONOMICS

Cost–effectiveness analysis in pharmacogenomics

(2010) Katherine Payne et al.   PHARMACOGENOMICS

First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America

(2009) Benjamin Young et al.   AIDS

Cost-effectiveness of genotype-guided warfarin therapy for anticoagulation in elderly patients with atrial fibrillation

(2009) Julio A. Leey et al.   American Journal Geriatric Pharmacotherapy

Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer

(2009) Heather Taffet Gold et al.   CANCER

Cost-Effectiveness of Genotype-Guided Warfarin Dosing for Patients With Atrial Fibrillation

(2009) Amanda R. Patrick et al.  

Personalized medicine and disruptive innovation: Implications for technology assessment

(2009) Kevin A Schulman et al.   GENETICS IN MEDICINE

The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group

(2009) Steven M Teutsch et al.   GENETICS IN MEDICINE

The HTA Core Model: A novel method for producing and reporting health technology assessments

(2009) Kristian Lampe et al.   INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE

Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations

(2009) Guido Sauter et al.   JOURNAL OF CLINICAL ONCOLOGY

Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors

(2009) T John et al.   ONCOGENE

Pharmacoeconomic Evaluations of Pharmacogenetic and Genomic Screening Programmes

(2009) Stefan Vegter et al.   PHARMACOECONOMICS

The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV

(2008) Bruce R Schackman et al.   AIDS

HER2+ Breast Cancer

(2008) David G. Hicks et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Using Pharmacoeconomics to Value Pharmacotherapy

(2008) JW Hay   CLINICAL PHARMACOLOGY & THERAPEUTICS

HLA-B*5701 Screening for Hypersensitivity to Abacavir

(2008) Simon Mallal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cost–effectiveness ofUGT1A1genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer

(2008) Marko Obradovic et al.   PHARMACOGENOMICS

The Potential Clinical and Economic Outcomes of Pharmacogenomic Approaches to EGFR-Tyrosine Kinase Inhibitor Therapy in Non–Small-Cell Lung Cancer

(2008) Josh J. Carlson et al.   VALUE IN HEALTH

Economic Evaluation for Devices and Drugs—Same or Different?

(2008) Michael Drummond et al.   VALUE IN HEALTH